Medicamen Biotech Ltd

For the fifth consecutive session, Medicamen Biotech Ltd has closed lower, hitting a fresh 52-week low of Rs 217.65 on 8 Jun 2026. This marks a significant decline amid a broader market environment that itself is under pressure, but the stock’s underperformance is notably sharper.

Medicamen Biotech Ltd has demonstrated a notable financial turnaround in the quarter ended March 2026, reversing a negative trend to post its highest quarterly revenue and profit metrics in recent history. Despite ongoing sector headwinds and a challenging broader market environment, the micro-cap pharmaceutical company’s latest results signal a potential inflection point in its operational performance.

Medicamen Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 May 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 28 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and technical outlook.

Medicamen Biotech Ltd., a research-led pharmaceutical company with presence across 40+ countries, reported consolidated net profit of ₹3.86 crores for Q4 FY26, marking a substantial 76.26% quarter-on-quarter surge and a 59.50% year-on-year increase. However, the micro-cap pharma player, with a market capitalisation of ₹370.00 crores, continues to grapple with structural profitability challenges, elevated valuation multiples, and persistent underperformance against sector benchmarks that have pushed the stock down 33.70% over the past year.

Medicamen Biotech Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from an attractive to a fair rating. This change reflects evolving market perceptions amid challenging sector dynamics and a mixed financial performance, prompting investors to reassess the stock’s price attractiveness relative to its historical and peer benchmarks.

Medicamen Biotech Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating despite its historically high price-to-earnings (P/E) ratio. This change reflects evolving market perceptions amid a challenging performance backdrop, with the company’s micro-cap status and sector dynamics playing a crucial role in investor sentiment.

Medicamen Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 17 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Medicamen Biotech Ltd has seen a notable shift in its valuation parameters, moving from an attractive to a fair rating, reflecting changing market perceptions and relative peer positioning. Despite a recent downgrade in its Mojo Grade to Sell from Strong Sell, the company’s valuation metrics reveal a complex picture of price attractiveness amid sector volatility and competitive pressures.

Medicamen Biotech Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting a nuanced shift in its technical outlook despite ongoing financial challenges. The change, effective from 5 May 2026, is driven primarily by an improvement in technical indicators, while valuation and financial trends continue to present a mixed picture for investors.

Medicamen Biotech Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 Feb 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 05 May 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Medicamen Biotech Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 14 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 24 April 2026, providing investors with the latest insights into the company’s performance and outlook.

Medicamen Biotech Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair rating. Despite a recent uptick in its share price, the company’s elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios, alongside subdued returns on capital, have raised concerns among investors and analysts alike.

Medicamen Biotech Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 14 February 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are based on the company’s current position as of 13 April 2026, providing investors with the latest comprehensive view of the stock’s performance and prospects.

Medicamen Biotech Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 April 2026, providing investors with an up-to-date view of its fundamentals, returns, and technical outlook.

For the second consecutive session, Medicamen Biotech Ltd has seen its share price slide further, hitting a fresh 52-week low of Rs 225 on 30 Mar 2026. This decline extends a recent losing streak that has erased nearly 10% of its value over two days, underscoring persistent selling pressure amid a challenging market backdrop.

A sharp decline in Medicamen Biotech Ltd has pushed the stock to a fresh 52-week low of Rs 234.35 on 27 Mar 2026, marking a significant 47.95% drop over the past year. This downturn comes amid broader market weakness and persistent underperformance relative to benchmarks and peers.